Strides Pharma Science Ltd Shows Positive Momentum Shift Amid Mixed Technical Signals

Technical Trend Shift and Price Movement

On 7 Apr 2026, Strides Pharma Science Ltd closed at ₹980.90, marking a 1.15% increase from the previous close of ₹969.75. The stock traded within a range of ₹964.35 to ₹991.50 during the day, inching closer to its 52-week high of ₹1,024.90. This price action aligns with the recent upgrade in the technical trend from mildly bearish to mildly bullish, signalling a potential inflection point for investors.

The stock’s resilience is further highlighted by its strong relative performance against the Sensex. Over the past week, Strides Pharma returned 4.6%, outpacing the Sensex’s 3.0%. The one-month return is particularly impressive at 13.39%, contrasting sharply with the Sensex’s negative 6.1%. Year-to-date, Strides has gained 8.71%, while the Sensex has declined by 13.04%. This outperformance extends over longer horizons as well, with a one-year return of 56.07% versus the Sensex’s -1.67%, and a remarkable three-year return of 574.91% compared to the Sensex’s 23.86%.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator presents a mixed but cautiously optimistic picture. On the weekly chart, the MACD is bullish, suggesting upward momentum in the near term. However, the monthly MACD remains mildly bearish, indicating that longer-term momentum has yet to fully confirm a sustained uptrend. This divergence between weekly and monthly MACD readings suggests that while short-term traders may find opportunities, longer-term investors should remain vigilant for confirmation signals.

Complementing the MACD, the Know Sure Thing (KST) indicator is bullish on the weekly timeframe but mildly bearish on the monthly, reinforcing the notion of a nascent recovery that requires further validation over coming months.

RSI and Overbought/Oversold Conditions

The Relative Strength Index (RSI) offers a more cautious view. On the weekly scale, the RSI is neutral, providing no clear buy or sell signal. Conversely, the monthly RSI is bearish, indicating that the stock may be experiencing some underlying weakness or overextension on a longer-term basis. This bearish monthly RSI suggests that despite recent gains, the stock could face resistance or consolidation before a more decisive rally unfolds.

Moving Averages and Bollinger Bands

Daily moving averages currently present a mildly bearish stance, signalling that short-term price action has not yet decisively broken above key average levels. This could imply some near-term volatility or profit-taking. However, the Bollinger Bands tell a more encouraging story: both weekly and monthly Bollinger Bands are bullish, indicating that price volatility is expanding upwards and the stock is trending towards higher price bands. This expansion often precedes sustained upward moves, suggesting that Strides Pharma may be gearing up for a stronger rally.

Volume and On-Balance Volume (OBV) Analysis

Volume trends provide additional insight into the stock’s technical health. The On-Balance Volume (OBV) indicator shows no clear trend on the weekly chart but is bullish on the monthly timeframe. This suggests that while short-term volume flows are inconclusive, longer-term accumulation by investors is underway, supporting the bullish case for Strides Pharma.

Dow Theory and Broader Market Context

According to Dow Theory assessments, both weekly and monthly trends are mildly bullish. This alignment with broader market theory indicates that the stock is participating in a general uptrend, albeit with some caution warranted given the mild nature of the signals. The pharmaceutical and biotechnology sector, to which Strides belongs, remains a focal point for investors seeking growth amid healthcare innovation and demographic tailwinds.

Mojo Score and Analyst Ratings

Strides Pharma Science Ltd currently holds a Mojo Score of 56.0, categorised as a Hold. This represents an upgrade from a previous Sell rating on 6 Apr 2026, reflecting improved technical and fundamental outlooks. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility but also greater growth potential. Investors should weigh this rating alongside technical signals and broader market conditions when considering exposure.

Long-Term Performance and Investment Implications

Strides Pharma’s long-term returns have been exceptional, with a five-year gain of 146.47% and a ten-year return of 98.63%. These figures significantly outperform the Sensex’s respective returns of 50.62% and 197.61% over the same periods, underscoring the stock’s capacity for substantial capital appreciation. The three-year return of 574.91% is particularly striking, reflecting a period of rapid growth and investor confidence.

However, the divergence between short-term technical indicators and longer-term momentum signals suggests that investors should approach with a balanced perspective. While weekly indicators point to bullish momentum, monthly signals urge caution, highlighting the importance of monitoring key levels such as the 52-week high of ₹1,024.90 and the daily moving averages.

Conclusion: Navigating Mixed Signals

Strides Pharma Science Ltd is currently at a technical crossroads, with a shift towards a mildly bullish trend supported by weekly MACD, Bollinger Bands, and Dow Theory signals. Yet, monthly indicators such as RSI and MACD remain mildly bearish, signalling that the stock may face resistance or consolidation in the near term. The daily moving averages’ mildly bearish stance further emphasises the need for caution.

Investors should consider the stock’s strong relative performance against the Sensex and its impressive long-term returns, balanced against the mixed technical signals. Those with a medium to long-term horizon may find value in accumulating on dips, while short-term traders should watch for confirmation of momentum through sustained breaks above key resistance levels.

Overall, Strides Pharma Science Ltd’s upgraded Mojo Grade to Hold reflects a cautious optimism, suggesting that while the stock is not yet a definitive buy, it is showing signs of recovery and potential for further gains in the evolving market environment.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →